Table 2. Evolution of Trypanosoma cruzi-specific humoral immune responses according to changes in T cell responses during long-term follow-up of benznidazole-treated subjects.
| Patient group | ELISPOT responses(from Table 1) | Changes in Serology | |||||
|---|---|---|---|---|---|---|---|
| ELISA | IHA | IFI | No of subjects with seroconversion/total evaluated (%) A | Multiplex serology (%) B | Months of follow-up (range) | ||
| 1 | Rebound | 0.0015 C | 0.0052 C | NS | 2/12 (17) | 11/12 (92) E | 65–150 |
| 2 | Decreased | 0.0205 C | 0.0072 C | NS | 5/8 (63) D | 6/7 (86) F (*) | 48–132 |
| 3 | Became detectable | NS | NS | NS | 0/5 | 2/5 (40) | 80–137 |
| 4 | Unchanged | NS | NS | NS | 0/8 | 2/8 (25) | 48–96 |
A No. of subjects with negative findings postreatment for 2 out of 3 or 3 out 3 conventional serological tests.
B No. of subjects/total evaluated with a 50% decrease in mean florescence intensity for > 1 recombinant Trypanosoma cruzi protein in the14-protein multiplex panel.
C P, antibody titers post-treatment compared with pretreatment values, by the Mann Whitney U test
D P < 0.05 compared with group 4, by the Fisher exact test.
E P < 0.01 compared with group 4, by the Fisher exact test.
F P < 0.05 compared with group 4, by the Fisher exact test.
(*) No sample available for one patient.
ELISA, enzyme-linked immunosorbent assay; IHA, indirect hemagglutination; IFI, indirect immunofluorescence; NS, no significant change relative to pretreatment values.